tert-butyl 3-(4-(1-((1-(m-tolyl)-1H-pyrazol-4-yl)oxy)butyl)benzamido)propanoate | 1355533-95-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: tert-butyl 3-(4-(1-((1-(m-tolyl)-1H-pyrazol-4-yl)oxy)butyl)benzamido)propanoate
• CAS: 1355533-95-7
• 化学式: C₂₈H₃₅N₃O₄
• 分子量: 477.604
• InChiKey: QHYFHVRIZVZSFW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.56
• 重原子数：
  35.0
• 可旋转键数：
  10.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  82.45
• 氢给体数：
  1.0
• 氢受体数：
  6.0

反应信息

• 作为反应物：
  描述：

  tert-butyl 3-(4-(1-((1-(m-tolyl)-1H-pyrazol-4-yl)oxy)butyl)benzamido)propanoate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 反应 2.5h， 生成 3-[[4-[1-[1-(3-Methylphenyl)pyrazol-4-yl]oxybutyl]benzoyl]amino]propanoic acid
  参考文献：
  名称：

  A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity

  摘要：

  A novel series of glucagon receptor antagonists has been discovered. These pyrazole ethers and aminopyrazoles have lower molecular weight and increased polarity such that the molecules fall into better drug-like property space. This work has culminated in compounds 44 and 50 that were shown to have good pharmacokinetic attributes in dog, in contrast to rats, in which clearance was high; and compound 49, which demonstrated a dose-dependent reduction in glucose excursion in a rat glucagon challenge experiment. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.113
• 作为产物：
  描述：

  ethyl 4-(1-((1H-pyrazol-4-yl)oxy)butyl)benzoate 在 trans-N,N'-dimethyl-1,2-cyclohexyldiamine 、 copper(l) iodide 、 O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 水 、 potassium carbonate 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 二氯甲烷 、 甲苯 为溶剂， 反应 56.0h， 生成 tert-butyl 3-(4-(1-((1-(m-tolyl)-1H-pyrazol-4-yl)oxy)butyl)benzamido)propanoate
  参考文献：
  名称：

  A novel series of glucagon receptor antagonists with reduced molecular weight and lipophilicity

  摘要：

  A novel series of glucagon receptor antagonists has been discovered. These pyrazole ethers and aminopyrazoles have lower molecular weight and increased polarity such that the molecules fall into better drug-like property space. This work has culminated in compounds 44 and 50 that were shown to have good pharmacokinetic attributes in dog, in contrast to rats, in which clearance was high; and compound 49, which demonstrated a dose-dependent reduction in glucose excursion in a rat glucagon challenge experiment. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.10.113